In Brief: Merck Vaqta
Executive Summary
Merck Vaqta: Company expects FDA action on its submission for the hepatitis A vaccine by March 30, the 12-month user fee deadline for the vaccine PLA. "The Pink Sheet" (Feb. 5, p. 13) incorrectly characterized Vaqta in a story on the product's advisory committee review. Vaqta is a purified inactivated vaccine...